Payment overview · 2025
General Payments
$339.52
16 reported records · 11 companies
Healthcare provider profile · identity verified
John C. Arrabal, M.D.
Allopathic & Osteopathic Physicians|General Practice · CHESTERTOWN, MD · NPI 1295727063
Verified facts
What the public records show
CMS Open Payments records show John C. Arrabal, M.D. received $339.52 in general payments during 2025 across 16 reported records.
Exact Sciences Corporation accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.89 | 16.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.50 | 12.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.60 | 11.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.22 | 10.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.81 | 9.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.74 | 8.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.96 | 7.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.80 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.00 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.89 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.11 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.67 | 15 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $69.41 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.89 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.22 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| Binosto Normalized: binosto |
Drug | Radius Health, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 81 |
| Furosemide | Furosemide | 351 | 89 |
| Quetiapine Fumarate | Quetiapine Fumarate | 289 | 38 |
| Simvastatin | Simvastatin | 285 | 68 |
| Lisinopril | Lisinopril | 276 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 50 |
| Donepezil Hcl | Donepezil Hcl | 245 | 39 |
| Allopurinol | Allopurinol | 244 | 42 |
| Potassium Chloride | Potassium Chloride | 221 | 42 |
| Eliquis | Apixaban | 219 | 35 |
| Losartan Potassium | Losartan Potassium | 213 | 48 |
| Gabapentin | Gabapentin | 206 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 41 |
| Metformin Hcl | Metformin Hcl | 194 | 62 |
| Alprazolam | Alprazolam | 189 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 165 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 42 |
| Finasteride | Finasteride | 148 | 28 |
| Sertraline Hcl | Sertraline Hcl | 143 | 36 |
| Jardiance | Empagliflozin | 135 | 28 |
| Mirtazapine | Mirtazapine | 135 | 22 |
| Divalproex Sodium | Divalproex Sodium | 134 | 21 |
| Gemfibrozil | Gemfibrozil | 130 | 32 |
| Ezetimibe | Ezetimibe | 126 | 38 |
| Trazodone Hcl | Trazodone Hcl | 126 | 35 |
| Famotidine | Famotidine | 119 | 21 |
| Carvedilol | Carvedilol | 115 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 22 |
| Levetiracetam | Levetiracetam | 97 | 16 |
| Risperidone | Risperidone | 95 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 21 |
| Lorazepam | Lorazepam | 91 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 15 |
| Omeprazole | Omeprazole | 81 | 17 |
| Clonidine Hcl | Clonidine Hcl | 80 | 19 |
| Buspirone Hcl | Buspirone Hcl | 79 | 12 |
| Meloxicam | Meloxicam | 74 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 12 |
| Memantine Hcl | Memantine Hcl | 70 | suppressed |
| Myrbetriq | Mirabegron | 69 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 18 |
| Bupropion Xl | Bupropion Hcl | 67 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 67 | 22 |
| Ramipril | Ramipril | 67 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 14 |
| Azithromycin | Azithromycin | 64 | 50 |
| Amoxicillin | Amoxicillin | 62 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 13 |
| Alendronate Sodium | Alendronate Sodium | 60 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 40 |
| Pregabalin | Pregabalin | 57 | 11 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Fenofibrate | Fenofibrate | 53 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 28 |
| Baclofen | Baclofen | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Glipizide | Glipizide | 47 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 22 |
| Atenolol | Atenolol | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 17 |
| Spironolactone | Spironolactone | 40 | 12 |
| Cephalexin | Cephalexin | 39 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 13 |
| Ibuprofen | Ibuprofen | 36 | 17 |
| Temazepam | Temazepam | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | 11 |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Lacosamide | Lacosamide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.52 · 16 records | Exact Sciences Corporation | AUSTEDO XR, Binosto, CAPLYTA, FASENRA, JARDIANCE, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error